Drug Pricing Concerns May Hinder Rare Disease Lobbying Effort
Executive Summary
US Congressional staff pitch bills for rare disease patients and advocates to talk up while on Capitol Hill, but one that likely would delay generic entry may be a tough sell.
You may also be interested in...
Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure
Drug sponsors tell US GAO that orphan incentives don't draw them to the space, and several stakeholders say high prices and scientific discovery are the reason for the sector's growth.
At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
President Trump's 2019 federal budget proposal includes plan to exclude manufacturer discounts in the Medicare Part D coverage gap from beneficiaries' out-of-pocket totals, which may be at odds with recently enacted legislation.
Trump's Budget Surprise: FDA Gains 13% Increase
President Trump's FY 2019 budget request includes $473m in new non-user fee revenue for the US agency, a reversal of the previous year's request.